Mereo has signed a cooperation agreement with Rubric, which owns 14.3% of the rare disease and cancer biotech. Under the agreement terms, four new directors from Rubric will be appointed to Mereo’s board of directors as soon as possible, according to an Oct. 25 release. In tandem with these changes, current Mereo directors Peter Fellner, PhD; Brian Schwartz, MD; Abdul Mullick, PhD; and Anne Hyland are out. Source: Fierce Biotech 28/10/2022